regenHU Ltd

regenHU (operating as REGENHU SA) is a Swiss MedTech company founded in 2007 and headquartered in Villaz-Saint-Pierre, Fribourg, Switzerland. The company is one of the earliest and most established pioneers in 3D bioprinting, with a mission to enable transformational innovation in tissue engineering, regenerative medicine, and drug discovery. Since 2011, regenHU has been supported by the Nivalis Group. The company designs, develops, and manufactures complete bioprinting platforms that include instruments, software, and biomaterials.

regenHU's flagship product lines include the 3DDiscovery Evolution and 3DDiscovery Evolution BioSafety — high-precision research bioprinters offering convergence of multiple printing technologies including extrusion, inkjet, and laser-assisted bioprinting. The newer R-GEN series — comprising the R-GEN 100 and R-GEN 200 — represents the next generation of bioprinting stations. The R-GEN 200 features a biosafety enclosure and physiological temperature-controlled working zone optimized for printing living cellular constructs. Alongside the hardware, REGENHU developed SHAPER, a dedicated software platform that allows researchers to design 2D and 3D constructs, define biomaterials and labware, and manage entire bioprinting projects end-to-end.

Application domains include construction of human skin equivalents for wound healing research and cosmetic development, 3D tissue models for target validation and disease modeling, oral dose formulation research, and drug discovery characterization. The company serves academic research institutions, pharmaceutical companies, and biotech firms across Europe, North America, and Asia. With 11-50 employees, regenHU operates at the intersection of biotechnology, robotics, and precision engineering.